IV

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
Monday, October 2, 2023
Abstract (summary), IV, Publication, Multiple sclerosis, TG, II, RMS, Patient, MD, Treatment, Research, Therapy, Maintenance, Pharmaceutical industry, Oil

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy.

Key Points: 
  • NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy.
  • Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: https://apps.congrex.com/ectrims2023/en-GB/pag .
  • The late breaking abstract will be available on October 11, 2023.
  • Details of the presentations are outlined below.

The DRIPBaR Announces Newest Location in Old Saybrook, CT!

Retrieved on: 
Friday, September 29, 2023
OLD, Au, Health, IV, Mental health, Restaurant, Fireworks, Medical device

OLD SAYBROOK, Conn., Sept. 29, 2023 /PRNewswire-PRWeb/ -- The DRIPBaR is excited to announce the opening of its newest location in Old Saybrook, CT on October 5th. This marks the newest location for the franchise, with approximately 600+ additional locations in the pipeline.

Key Points: 
  • The DRIPBaR is excited to announce the opening of its newest location in Old Saybrook, CT on October 5th where IV vitamin therapy and IM Quick Shots will be offered.
  • OLD SAYBROOK, Conn., Sept. 29, 2023 /PRNewswire-PRWeb/ -- The DRIPBaR is excited to announce the opening of its newest location in Old Saybrook, CT on October 5th.
  • The DRIPBaR Old Saybrook will offer all of the standard DRIPBaR services, including IV vitamin therapy and IM Quick Shots .
  • The DRIPBaR Old Saybrook is owned and operated by Ricky and Supawan (Tai) Au, who are excited to bring new wellness options to Old Saybrook and beyond.

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retrieved on: 
Friday, September 29, 2023
General Health, Health, Medical Supplies, Medical Devices, Injection, Maintenance, IV, Injury, RVP, Risk, NYSE, Bloodstream infections, Safety, Syringe, Medical device, Online shopping, Retractable hardtop

Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.

Key Points: 
  • Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.
  • The dividends cover the period beginning July 1, 2023 through September 30, 2023.
  • The dividends will be paid on October 20, 2023 to shareholders of record as of the close of business on October 10, 2023.
  • Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle.

Global Blood Transfusion Set Market Expected to Rebound with 3.0% CAGR, Reaching $591 Million by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Health, Other Health, Male, IV, Prevalence, ICU Medical, Pump, Baxter, Cancer, Luer, Domination, Research, BD (company), Blood transfusion, Chronic, BD, Medical device, Pharmaceutical industry, Alaris

In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.

Key Points: 
  • In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.
  • Currently, market leaders in the global blood transfusion set market include Becton Dickinson (BD), Baxter, and ICU Medical.
  • Rebound Expected: The global blood transfusion set market is projected to rebound with a CAGR of 3.0%, reaching a valuation of $591 million, following a 3.5% decline in 2023.
  • Dominant Players: Key players such as Becton Dickinson (BD), Baxter, and ICU Medical currently dominate the global blood transfusion set market.

Dr. Irfan Atcha and New Teeth Chicago Dental gets an award in Best in Illinois Magazine

Retrieved on: 
Friday, September 29, 2023
IV, Dental implant, Hope, Multimedia, Patient, Cosmetic dentistry, DDS, Dental care, Rest, Complex, Dentistry

CHICAGO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- Leading Implantologist Dr. Irfan Atcha, DDS & New Teeth Chicago Dental Implant Center. was recently recognized for his work with patients and got featured in BEST in Illinois magazine. He was selected to win a Top Doctor award as Chicago's Top Implant and Cosmetic Dentist and America's Best Dentist over the last 8 years. The Best in Illinois feature is based patient reviews, experience and reputation and a thorough overview of the nominated dental practices. The coveted 2023 award/feature is a testament to the hard work and dedication the Chicago area's most well-known dental implant specialist puts into his practice. "I am honored to be recognized for my achievements in this field," says Dr. Atcha. "I couldn't have done it without my wonderful staff and my generous patients who reviewed me for this award."

Key Points: 
  • Dr. Irfan Atcha, DDS DICOI of the New Teeth Dental practice in Chicago, recently won an award for cosmetic dentistry and dental implants and get featured in Best in Illinois magazine.
  • CHICAGO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- Leading Implantologist Dr. Irfan Atcha, DDS & New Teeth Chicago Dental Implant Center.
  • was recently recognized for his work with patients and got featured in BEST in Illinois magazine.
  • The ever-growing dental implant practice/center in Chicago, Illinois specializes in state-of-the-art dental implant procedures.

PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free

Retrieved on: 
Thursday, September 28, 2023
Biotechnology, Pharmaceutical, Medical Supplies, Oncology, General Health, Health, Genetics, Clinical Trials, Vaccine, Injection, DNA, Probability, Use, IV, CPI, Prognosis, COVID, SCIB1, Patient, Ipilimumab, III, ORR, Nivolumab, Pharmaceutical industry

The vaccine is delivered by needle-free injection with the PharmaJet Stratis® System , which patients prefer over needle and syringe delivery.

Key Points: 
  • The vaccine is delivered by needle-free injection with the PharmaJet Stratis® System , which patients prefer over needle and syringe delivery.
  • Historically, the prognosis of patients with unresectable stage III and IV melanoma, when surgery is not an option, has been poor: Median overall survival is only 6.2 months1.
  • Scancell’s immunotherapy platform aims to improve on this prognosis using the body’s immune system to identify, attack and destroy tumors.
  • Chris Cappello, President and CEO, PharmaJet commented, “We are pleased to be partnering with Scancell as they move forward with the second phase of the Phase 2 trial.

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

Retrieved on: 
Wednesday, September 27, 2023
Infection, AMB, Fungal infection, IV, Toxicity, Patient, Access, Microsoft Access, Pharmaceutical industry, Vaccine

"We are delighted to participate in this important scientific conference and to highlight additional clinical evidence from our Expanded Access Program supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections," said Dr. Matkovits.

Key Points: 
  • "We are delighted to participate in this important scientific conference and to highlight additional clinical evidence from our Expanded Access Program supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections," said Dr. Matkovits.
  • "The efficacy of AMB is well established, but use of this potent fungicidal drug is typically administered selectively and only to patients with severe disease because of its toxicity.
  • MAT2203 reduces the systemic toxicity associated with IV AMB by delivering drug directly to targeted cells at the sites of infection, supporting a favorable safety profile with the additional benefit of oral administration.
  • "The compelling compassionate use data we will be presenting at IDWeek as part of our pipeline overview support our strategy to develop an ideal antifungal agent for the treatment of a variety of invasive fungal infections while potentially having a dramatic impact on the cost of treating these deadly diseases," she added.

Skoulas DDS - The SF Cosmetic Dentist of San Francisco Announces New Website

Retrieved on: 
Tuesday, September 26, 2023
American Dental Association, Dental assistant, Dental implant, Cosmetic dentistry, Academy of General Dentistry, Twilight anesthesia, IV, American Academy of Cosmetic Dentistry, UCLA School of Dentistry, American Academy, Blog, Patient, SAN, DDS, Dental care, Health, Postgraduate training in general dentistry, Dental, Commerce, Online shopping, Dentistry

SAN FRANCISCO, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Skoulas DDS - The SF Cosmetic Dentist, a premier dental clinic in San Francisco, CA, is pleased to announce the launch of a new and enhanced website at https://www.skoulasdds.com. The new website offers a streamlined design and user experience, making it easier to find the information that you need. It also has a variety of new features, including a more user-friendly design, a list of services offered, a blog, and more relevant content.

Key Points: 
  • Skoulas DDS - The SF Cosmetic Dentist, a premier dental clinic in San Francisco, CA, is pleased to announce the launch of a new and enhanced website at https://www.skoulasdds.com .
  • SAN FRANCISCO, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Skoulas DDS - The SF Cosmetic Dentist, a premier dental clinic in San Francisco, CA, is pleased to announce the launch of a new and enhanced website at https://www.skoulasdds.com .
  • Skoulas DDS - The SF Cosmetic Dentist is a highly awarded dental practice that specializes in cosmetic dentistry and advanced dental care.
  • Services provided by Skoulas DDS - The SF Cosmetic Dentist include:
    Sedation dentistry: Dental sedation, conscious sedation, and IV anesthesia for dental procedures.

OHBA Congratulates the 2023 Awards of Distinction Winners

Retrieved on: 
Wednesday, September 20, 2023
Human, Central Park, Twenty-five Year Award, IV, Engineering, Professional, BILD, Planner, Creativity, Lily Lake, AOD, Moen, Daniels, Construction, Federated Insurance Company of Canada, AMST, Interior design, Property management

Collingwood, Ontario, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The Ontario Home Builders’ Association (OHBA) is pleased to announce the 2023 OHBA Awards of Distinction (AoD) winners.

Key Points: 
  • Collingwood, Ontario, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The Ontario Home Builders’ Association (OHBA) is pleased to announce the 2023 OHBA Awards of Distinction (AoD) winners.
  • This annual awards program recognizes the creativity, innovation, and excellence of builders, renovators, developers, and service professionals within Ontario’s dynamic residential construction industry.
  • Categories span seven groupings, including architectural design, renovation, room design, image & advertising, on-site sales presentation, and the coveted prestige awards.
  • The winners were revealed last night at the AoD Gala presented by Federated Insurance and hosted by comedian and TV personality Graham Chittenden.

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Retrieved on: 
Friday, September 22, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Hypersensitivity, Neutropenia, Contraindication, Maintenance, Lymphocyte, Acute leukemia, Pancreatitis, Febrile neutropenia, IV, Civil service commission, MWF, Diarrhea, ALL, Acute lymphoblastic leukemia, IM, COG, Appetite, Abdominal pain, European Commission, NSAA, Sepsis, LBL, Vomiting, Patient, European, Anemia, Nausea, Headache, EC, Jazz Pharmaceuticals, Thrombocytopenia, Safety, Fatigue, Vaccine, Ligand Pharmaceuticals, Fever

“We congratulate our partner Jazz on its receipt of approval for Enrylaze® from the European Commission, expanding the market opportunity for one of our key commercial-stage products,” said Todd Davis, CEO of Ligand Pharmaceuticals.

Key Points: 
  • “We congratulate our partner Jazz on its receipt of approval for Enrylaze® from the European Commission, expanding the market opportunity for one of our key commercial-stage products,” said Todd Davis, CEO of Ligand Pharmaceuticals.
  • The determination of efficacy was based on demonstration of the achievement and maintenance of nadir serum asparaginase activity (NSAA) levels ≥ 0.1 U/mL.
  • Overall, the safety profile of JZP458 was consistent with the reported safety information for patients with ALL/LBL receiving asparaginase with combination chemotherapy.
  • The European Commission approval extends to all European Union Member states, as well as Iceland, Norway, and Liechtenstein.